Compare BMO & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMO | BDX |
|---|---|---|
| Founded | 1817 | 1897 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6B | 55.5B |
| IPO Year | N/A | 1962 |
| Metric | BMO | BDX |
|---|---|---|
| Price | $132.35 | $202.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $163.00 | ★ $206.38 |
| AVG Volume (30 Days) | 533.8K | ★ 1.9M |
| Earning Date | 02-24-2026 | 02-04-2026 |
| Dividend Yield | ★ 3.46% | 2.04% |
| EPS Growth | ★ 20.29 | N/A |
| EPS | ★ 8.16 | 5.82 |
| Revenue | ★ $23,303,458,020.00 | $21,840,000,000.00 |
| Revenue This Year | $16.77 | $4.02 |
| Revenue Next Year | $4.96 | $3.37 |
| P/E Ratio | ★ $16.29 | $35.29 |
| Revenue Growth | ★ 12.48 | 8.24 |
| 52 Week Low | $85.40 | $162.29 |
| 52 Week High | $135.01 | $251.99 |
| Indicator | BMO | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 61.17 |
| Support Level | $129.70 | $192.48 |
| Resistance Level | $135.01 | $197.24 |
| Average True Range (ATR) | 2.00 | 3.24 |
| MACD | 0.18 | 0.43 |
| Stochastic Oscillator | 72.71 | 66.30 |
Bank of Montreal is a diversified financial-services provider based in North America with over CAD 1.4 trillion in assets. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the US.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.